Moleculin Biotech (MBRX) News Today $0.67 0.00 (-0.43%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.62 -0.06 (-8.23%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on TuesdayAugust 10 at 2:47 AM | americanbankingnews.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer ...August 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation UpdateAugust 1, 2025 | tipranks.comMoleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 31, 2025 | finanznachrichten.deMoleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 30, 2025 | globenewswire.comMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comMoleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMoleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic PartnershipsJuly 17, 2025 | globenewswire.comMoleculin Biotech enters $6.5 million at-the-market equity offering ...July 13, 2025 | investing.comMoleculin Biotech Enters New Stock Offering AgreementJuly 11, 2025 | tipranks.comMoleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 ... - NasdaqJuly 11, 2025 | nasdaq.comMoleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9, 2025 | finanznachrichten.deMoleculin Biotech receives approval for pivotal Phase 2B/3 study of AnnamycinJuly 9, 2025 | msn.comMoleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9, 2025 | globenewswire.comSeveral Insiders Invested In Moleculin Biotech Flagging Positive NewsJuly 4, 2025 | finance.yahoo.comMoleculin Biotech Faces Nasdaq Delisting WarningJune 27, 2025 | tipranks.comMBRX Moleculin Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comMoleculin Biotech, Inc. (NASDAQ:MBRX) CFO Acquires $99,999.90 in StockJune 24, 2025 | insidertrades.comMoleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AMLJune 20, 2025 | nasdaq.comMoleculin Biotech prices $5.9M public offering; shares down about 47%June 20, 2025 | msn.comMoleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E WarrantsJune 20, 2025 | quiverquant.comQMoleculin Announces $5.9 Million Public OfferingJune 20, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical StudyJune 18, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 18, 2025 | globenewswire.comMoleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | globenewswire.comMoleculin Biotech announces ‘What This Means’ virtual investor segmentJune 12, 2025 | finance.yahoo.comMoleculin Participates in Virtual Investor “What This Means” SegmentJune 11, 2025 | globenewswire.comMoleculin Biotech Hosts Key Opinion Leaders EventJune 5, 2025 | tipranks.comMoleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)June 5, 2025 | globenewswire.comMoleculin Biotech Reports Positive Annamycin Trial ResultsJune 4, 2025 | msn.comMoleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)June 4, 2025 | globenewswire.comMoleculin Biotech files to sell 10.99M shares of common stock, warrantsJune 2, 2025 | msn.comEarnings call transcript: Moleculin Biotech reports Q1 2025 updatesMay 15, 2025 | uk.investing.comMOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly EarningsMay 15, 2025 | nasdaq.comMoleculin Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Expands Phase 3 Trial of Annamycin for R/R AML to Nine EU Countries, Enrollment UnderwayMay 12, 2025 | quiverquant.comQMoleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | globenewswire.comMoleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and WebcastMay 7, 2025 | globenewswire.comMoleculin secures two new US patents for cancer drug AnnamycinMay 6, 2025 | investing.comMoleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML TreatmentMay 6, 2025 | quiverquant.comQMoleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for AnnamycinMay 6, 2025 | globenewswire.comMoleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. PatentsMay 5, 2025 | globenewswire.comMoleculin reports Annamycin cancer drug synergy at AACR meetingApril 30, 2025 | investing.comMoleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer TherapiesApril 30, 2025 | nasdaq.comMoleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic CancerApril 29, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation OnlineApril 21, 2025 | tipranks.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼-0.520.49▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼52▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANRO News Today EPIX News Today EXOZ News Today CABA News Today BYSI News Today ELUT News Today MIST News Today CELU News Today IPA News Today SRZN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
